Executive Summary

Executive Summary

The clinical research industry represents a significant source of healthcare innovationand economic prosperity for countries. As a primary gateway into Asia and a centralplayer in the region, Thailand is an emerging provider of clinical trials. World-classinfrastructure, a universal healthcare system, and national policies that supporta developing clinical research industry make Thailand well positioned to pursuefurther growth in the clinical research industry.

The current status of the industry suggests that these underlying benefits forconducting clinical research in Thailand have not been fully realised and that othercountries in the region, such as South Korea and Taiwan, have been able to moresuccessfully attract clinical trials. Over the 2010-2015 period, over 4,000 clinicaltrials commenced in South Korea, around 2,000 in Taiwan but fewer than 1,000 (967)in Thailand .

The Pharmaceutical Research and Manufacturers Association (PReMA) in Thailandcommissioned Deloitte Access Economics to provide a detailed and objective analysisof the economic and health related benefits of clinical research in Thailand. The teamadopted a mixed methods approach to the study which comprised a survey,interviews and desktop analysis.

408/85, 19th Floor, Phaholyothin Place Bldg., Phaholyothin Road, Samsennai, Phayathai, Bangkok 10400 Thailand

Phone : (02) 619-0232-6
Fax : (02) 619-0237
Email : [email protected]
PReMA Thailand